Clinical trials: Tuberculosis
Tuberculosis (TB)
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults
This Phase I study will evaluate the safety and immunogenicity of two doses GSK Biologicals' candidate TB vaccine (692342) according to a 0, 1, 2 months schedule in PPD-negative adults.
- Trial name
- NCT00730795
- Testing
- GSK's candidate Mycobacterium tuberculosis vaccine 692342
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis Infection
Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years
The aim of the study is to investigate safety, reactogenicity and immunogenicity of the TB/Flu-05E single-dose intranasal vaccine for the prevention of Tuberculosis infection in BCG-vaccinated Volunteers aged 18-50 years.
- Trial name
- NCT05945498
- Testing
- TB/Flu-05E vaccine
- Where
- Russia
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Tatyana Zubkova
Latent Tuberculosis, Latent Tuberculosis Bacteriology and Histology Unknown
Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis
This is a Phase I, open-label, dose-escalation study with three study groups. This study will be conducted in 25 HIV negative subjects, 17 of whom will have Latent Tuberculosis Infection (LTBI) and 8 of whom will not have LTBI at…
- Trial name
- NCT01967134
- Testing
- H56:IC31
- Where
- South Africa
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Aeras
Latent Tuberculosis Infection
Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients.
- Trial name
- NCT05746611
- Testing
- Recombinant Mycobacterium tuberculosis fusion protein for injection, TB-PPD was injected
- Where
- China
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Tuberculosis (TB)
A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.
A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in adolescents and adults aged 14-45 years…
- Trial name
- NCT06272812
- Testing
- MTBVAC
- Where
- 16 sites in Kenya, South Africa and 1 more
- Volunteers
- 5,531 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV Infection, Tuberculosis
Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV
Tuberculosis (TB) is highly endemic in sub-Saharan Africa. The increased burden of TB in settings with high prevalence of the Human Immunodeficiency Virus (HIV) is associated with high rates of transmission of Mycobacterium…
- Conditions
- HIV Infection, Tuberculosis, Pneumocystis Jiroveci Pneumonia
- Trial name
- NCT00080119
- Testing
- Isoniazid (INH), Trimethoprim/Sulfamethoxazole (TMP/SMX)
- Where
- 6 sites in Botswana, South Africa
- Volunteers
- 1,354 people, healthy volunteers welcome
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Tuberculosis Infection
Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
Diagnosis of active and latent pulmonary tuberculosis, as well as extrapulmonary tuberculosis, is still a major challenge of TB control in China.
- Trial name
- NCT04148053
- Testing
- TB-antigen responsive T cell markers
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tongji University
Tuberculosis
The Impact of Vitamin D on Tuberculosis Among Koreans
Vitamin D has been regarded to be beneficial to tuberculosis (TB) patients. The aim of this study is to elucidate the role of vitamin D deficiency in development and treatment outcomes among Korean TB patients.
- Trial name
- NCT01137370
- Where
- South Korea
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Tuberculosis
Study of Latent Tuberculosis Infection (LTBI) by High Resolution Scanner
It is traditionally considered that someone with a positive tuberculin skin test (TST) (and/or positive result in Cell Interferon-Gamma Release Assay (TIGRA), depending on the different countries' guidelines) is infected but not…
- Trial name
- GRANLATHU (NCT00904956)
- Where
- 3 sites in Spain
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Germans Trias i Pujol Hospital
HIV/AIDS, Tuberculosis
Targeted Universal TB Testing With Simultaneous TPT Prescribing Among People Living With HIV in South Africa
Background: In 2023, the South African Department of Health introduced targeted universal TB testing (TUTT) at antiretroviral therapy (ART) initiation (irrespective of the presence of TB symptoms).
- Trial name
- TUTT-PT (NCT06739915)
- Testing
- TUTT-PT Intervention
- Where
- South Africa
- Volunteers
- 364 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Tuberculosis, Lung Cancer
Development and Application of Rapid Nucleic Acid Diagnostic Kits for Clinical Specimens
The purpose of this study is to study the Development and Application of Rapid Nucleic Acid Diagnostic Kits for Clinical Specimens.
- Trial name
- NCT01322685
- Where
- Taiwan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
Latent Tuberculosis
Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging
The purpose of this pilot study is to determine whether regularly scheduled medication reminder text messages (SMS) are effective in increasing latent tuberculosis infection (LTBI) treatment completion.
- Trial name
- TXT4MED (NCT02690818)
- Testing
- Regularly scheduled LTBI medication reminder text messages
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Arizona
HIV Infections, Tuberculosis
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
Rifampin (RIF) is used for the treatment of tuberculosis (TB), an infectious disease that affects many people with HIV. RIF was shown to lower concentrations and decrease the effectiveness of some anti-HIV drugs, including the…
- Trial name
- NCT00096850
- Testing
- Atazanavir, Rifampin, Ritonavir
- Where
- 3 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342
The purpose of this study is to assess the safety and immunogenicity of two doses of the TB vaccine administered according to a 0, 1 month schedule.
- Trial name
- NCT01669096
- Testing
- GSK Biologicals' investigational TB vaccine GSK 692342
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity, Pharmacokinetics
Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations
This study will find how weight affects the dosing of a drug called sulfamethoxazole and trimethoprim. Currently, the amount of sulfamethoxazole and trimethoprim a patient receives is the same regardless of the patient's weight.
- Conditions
- Obesity, Pharmacokinetics, MRSA, Tuberculosis
- Trial name
- NCT01167452
- Testing
- Sulfamethoxazole/trimethoprim
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
Tuberculosis
Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
Tuberculosis (TB) is a global public health concern and developing new treatment regimens is an important research priority. PA-824 is an experimental TB medication.
- Trial name
- NCT01571414
- Testing
- PA-824, Efavirenz (EFV), Lopinavir/Ritonavir (LPV/r)
- Where
- 4 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Tuberculosis Infection
Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants
The trial is designed as a phase III, double-blind, multicenter, randomized, single administration, active-controlled, parallel-group design with two groups of newborn infants receiving either VPM1002 or BCG SII (1:1 allocation)…
- Trial name
- VPM1002 (NCT04351685)
- Testing
- VPM1002, BCG SII
- Where
- 12 sites in Gabon, Kenya and 3 more
- Volunteers
- 6,940 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Tuberculosis
A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG
The dose of recombinant MVA used in the TB trials to date is relatively low compared with other trials using recombinant MVAs which have used up to 2.5 x 108pfu (A Hill, personal communication).
- Trial name
- NCT00465465
- Testing
- MVA 85A
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis, BCG Vaccination
Clinical Study to Evaluate Safety and Immunogenicity of Bacillus Calmette-Guerin (BCG) Delivery Via Novel Micronjet600 Device Compared to Those Via Conventional Needle
The purpose of this study is to evaluate safety and immunogenicity of Bacillus Calmette-Guerin (BCG) delivery via Novel Micronjet600 device compared to those via conventional needle.
- Trial name
- NCT04064554
- Testing
- BCG vaccination with MicronJet600, BCG vaccination with conventional needle
- Where
- South Korea
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Latent Tuberculosis
Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults
The aim of study is to evaluate the prevalence of latent TB in second generation immigrants from countries with high incidence of tuberculosis (above 20 of 100,000) compare to the control native Israelis without a family member…
- Trial name
- NCT02073669
- Testing
- Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)
- Where
- 2 sites in Israel
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center